nach oben

Erschienen in:

08.03.2018 | Review

Cancer immunotherapy in patients with brain metastases

verfasst von: Salvatore Caponnetto, Arianna Draghi, Troels Holz Borch, Marianna Nuti, Enrico Cortesi, Inge Marie Svane, Marco Donia

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

The exclusion of “real-world” patients from registration clinical trials of cancer immunotherapy represents a significant emerging issue. For instance, a large fraction of cancer patients develops brain metastases during the course of the disease, but results from large prospective clinical trials investigating this considerable proportion of the cancer patient population are currently lacking. To provide a useful tool for the clinician in a “real-world” setting, we have reviewed the available literature regarding the safety and efficacy of immune check-point inhibitors in patients with cancer metastatic to the brain. Overall, these data provide encouraging evidence that these therapeutic agents can induce intracranial objective responses, particularly in patients with asymptomatic and previously untreated brain metastases. Larger prospective studies are needed to confirm these initial results.

Sharma P, Allison JP (2015) The future of immune checkpoint therapy. Science 348(6230):56–61. https://doi.org/10.1126/science.aaa8172 CrossRefPubMed

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627–1639. https://doi.org/10.1056/NEJMoa1507643 CrossRefPubMedPubMedCentral

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23–34. https://doi.org/10.1056/NEJMoa1504030 CrossRefPubMedPubMedCentral

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P, CheckMate I (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813. https://doi.org/10.1056/NEJMoa1510665 CrossRefPubMedPubMedCentral

Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723. https://doi.org/10.1056/NEJMoa1003466 CrossRefPubMedPubMedCentral

Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Aren Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123–135. https://doi.org/10.1056/NEJMoa1504627 CrossRefPubMedPubMedCentral

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR, Group OAKS. (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066):255–265. https://doi.org/10.1016/S0140-6736(16)32517-X CrossRefPubMed

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A, investigators K- (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372 (26):2521–2532. https://doi.org/10.1056/NEJMoa1503093 CrossRefPubMed

Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Duran I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE, 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thastrom A, Abidoye OO, Fine GD, Bajorin DF, Group IMS (2017) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389 (10064):67–76. https://doi.org/10.1016/S0140-6736(16)32455-2 CrossRefPubMed

10.

Peters S, Bexelius C, Munk V, Leighl N (2016) The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treat Rev 45:139–162. https://doi.org/10.1016/j.ctrv.2016.03.009 CrossRefPubMed

11.

Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH (2005) Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 23(1):175–183. https://doi.org/10.1200/JCO.2005.04.177 CrossRefPubMed

12.

Donia M, Kimper-Karl ML, Hoyer KL, Bastholt L, Schmidt H, Svane IM (2017) The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials. Eur J Cancer 74:89–95. https://doi.org/10.1016/j.ejca.2016.12.017 CrossRefPubMed

13.

Carlino MS, Fogarty GB, Long GV (2012) Treatment of melanoma brain metastases: a new paradigm. Cancer J 18(2):208–212. https://doi.org/10.1097/PPO.0b013e31824b2890 CrossRefPubMed

14.

Nayak L, Lee EQ, Wen PY (2012) Epidemiology of brain metastases. Curr Oncol Rep 14(1):48–54. https://doi.org/10.1007/s11912-011-0203-y CrossRefPubMed

15.

Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan detroit cancer surveillance system. J Clin Oncol 22(14):2865–2872. https://doi.org/10.1200/JCO.2004.12.149 CrossRefPubMed

16.

Tsao MN (2015) Brain metastases: advances over the decades. Ann Palliat Med 4(4):225–232. https://doi.org/10.3978/j.issn.2224-5820.2015.09.01 PubMed

17.

Dagogo-Jack I, Gill CM, Cahill DP, Santagata S, Brastianos PK (2017) Treatment of brain metastases in the modern genomic era. Pharmacol Ther 170:64–72. https://doi.org/10.1016/j.pharmthera.2016.10.011 CrossRefPubMed

18.

Shin SM, Cooper BT, Chachoua A, Butler J, Donahue B, Silverman JS, Kondziolka D (2016) Survival but not brain metastasis response relates to lung cancer mutation status after radiosurgery. J Neurooncol 126(3):483–491. https://doi.org/10.1007/s11060-015-1986-8 CrossRefPubMed

19.

Zimmermann S, Dziadziuszko R, Peters S (2014) Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. Cancer Treat Rev 40(6):716–722. https://doi.org/10.1016/j.ctrv.2014.03.005 CrossRefPubMed

20.

Ryken TC, McDermott M, Robinson PD, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Gaspar LE, Kondziolka D, Linskey ME, Loeffler JS, Mehta MP, Mikkelsen T, Olson JJ, Paleologos NA, Patchell RA, Kalkanis SN (2010) The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96(1):103–114. https://doi.org/10.1007/s11060-009-0057-4 CrossRefPubMed

21.

Omidi Y, Barar J (2012) Impacts of blood-brain barrier in drug delivery and targeting of brain tumors. Bioimpacts 2(1):5–22. https://doi.org/10.5681/bi.2012.002 PubMedPubMedCentral

22.

Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, Adkins CE, Roberts A, Thorsheim HR, Gaasch JA, Huang S, Palmieri D, Steeg PS, Smith QR (2010) Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 16(23):5664–5678. https://doi.org/10.1158/1078-0432.CCR-10-1564 CrossRefPubMedPubMedCentral

23.

Steinmann D, Paelecke-Habermann Y, Geinitz H, Aschoff R, Bayerl A, Bolling T, Bosch E, Bruns F, Eichenseder-Seiss U, Gerstein J, Gharbi N, Hagg J, Hipp M, Kleff I, Muller A, Schafer C, Schleicher U, Sehlen S, Theodorou M, Wypior HJ, Zehentmayr F, van Oorschot B, Vordermark D (2012) Prospective evaluation of quality of life effects in patients undergoing palliative radiotherapy for brain metastases. BMC Cancer 12:283. https://doi.org/10.1186/1471-2407-12-283 CrossRefPubMedPubMedCentral

24.

Weber JS, Amin A, Minor D, Siegel J, Berman D, O’Day SJ (2011) Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res 21(6):530–534. https://doi.org/10.1097/CMR.0b013e32834d3d88 CrossRefPubMed

25.

Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13(5):459–465. https://doi.org/10.1016/S1470-2045(12)70090-6 CrossRefPubMed

26.

Queirolo P, Spagnolo F, Ascierto PA, Simeone E, Marchetti P, Scoppola A, Del Vecchio M, Di Guardo L, Maio M, Di Giacomo AM, Antonuzzo A, Cognetti F, Ferraresi V, Ridolfi L, Guidoboni M, Guida M, Pigozzo J, Chiarion Sileni V (2014) Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol 118(1):109–116. https://doi.org/10.1007/s11060-014-1400-y PubMedPubMedCentral

27.

Tarhini AA, Kirkwood JM (2008) Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers. Expert Opin Biol Ther 8(10):1583–1593. https://doi.org/10.1517/14712598.8.10.1583 CrossRefPubMed

28.

Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A (2013) Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31(5):616–622. https://doi.org/10.1200/JCO.2012.44.6112 CrossRefPubMedPubMedCentral

29.

Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, Ribas A (2009) Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 27(7):1075–1081. https://doi.org/10.1200/JCO.2008.19.2435 CrossRefPubMed

30.

Vonderheide RH, LoRusso PM, Khalil M, Gartner EM, Khaira D, Soulieres D, Dorazio P, Trosko JA, Ruter J, Mariani GL, Usari T, Domchek SM (2010) Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res 16(13):3485–3494. https://doi.org/10.1158/1078-0432.CCR-10-0505 CrossRefPubMed

31.

Calabro L, Morra A, Fonsatti E, Cutaia O, Fazio C, Annesi D, Lenoci M, Amato G, Danielli R, Altomonte M, Giannarelli D, Di Giacomo AM, Maio M (2015) Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med 3(4):301–309. https://doi.org/10.1016/S2213-2600(15)00092-2 CrossRefPubMed

32.

Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264. https://doi.org/10.1038/nrc3239 CrossRefPubMedPubMedCentral

33.

Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbe C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320–330. https://doi.org/10.1056/NEJMoa1412082 CrossRefPubMed

34.

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856–1867. https://doi.org/10.1056/NEJMoa1602252 CrossRefPubMedPubMedCentral

35.

Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540–1550. https://doi.org/10.1016/S0140-6736(15)01281-7 CrossRefPubMed

36.

Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD, Chow LQ (2016) Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 17(7):956–965. https://doi.org/10.1016/S1470-2045(16)30066-3 CrossRefPubMed

37.

Pembrolizumab (MK-3475) Versus standard treatment for recurrent or metastatic head and neck cancer (MK-3475-040/KEYNOTE-040). Identifier: NCT02252042. ClinicalTrials.gov.https://clinicaltrials.gov/ct2/show/NCT02252042?term=NCT02252042&rank=1. Accessed 27 Nov 2017

38.

FDA (2017) Novel drug approvals for 2016. FDA website. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm483775.htm. Accessed 21 Nov 2017

39.

FDA (2017) Novel drug approvals for 2017. FDA website. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm. Accessed 21 Nov 2017

40.

Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455–2465. https://doi.org/10.1056/NEJMoa1200694 CrossRefPubMedPubMedCentral

41.

Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32(10):1020–1030. https://doi.org/10.1200/JCO.2013.53.0105 CrossRefPubMedPubMedCentral

42.

Larkin J, Minor D, D’Angelo S, Neyns B, Smylie M, Miller WH Jr, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, Sosman J, Khushalani N, Schadendorf D, Hoeller C, Walker D, Kong G, Horak C, Weber J (2018) Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol 36(4):383–390. https://doi.org/10.1200/JCO.2016.71.8023 [Abstract from the European Society of Medical Oncology (ESMO) Congress, 2016].CrossRefPubMed

43.

Ahmed KA, Stallworth DG, Kim Y, Johnstone PA, Harrison LB, Caudell JJ, Yu HH, Etame AB, Weber JS, Gibney GT (2016) Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol 27(3):434–441. https://doi.org/10.1093/annonc/mdv622 CrossRefPubMed

44.

Parakh S, Park JJ, Mendis S, Rai R, Xu W, Lo S, Drummond M, Rowe C, Wong A, McArthur G, Haydon A, Andrews MC, Cebon J, Guminski A, Kefford RF, Long GV, Menzies AM, Klein O, Carlino MS (2017) Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. Br J Cancer 116(12):1558–1563. https://doi.org/10.1038/bjc.2017.142 CrossRefPubMed

45.

Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrish H, Yao X, Chiang V, Kluger HM (2016) Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17(7):976–983. https://doi.org/10.1016/S1470-2045(16)30053-5 CrossRefPubMedPubMedCentral

46.

Long GV, Atkinson V, Menzies AM, Lo S, Guminski AD, Brown MP, Gonzalez MM, Diamante K, Sandhu SK, Scolyer RA, Emmett L, McArthur GA (2017) A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): the anti-PD1 brain collaboration (ABC). [Abstract from the American Society of Clinical Oncology (ASCO) Annual Meeting, 2017]

47.

Haanen J, Hwu W-J, Martín-Algarra S, Hodi FS, Bhatia S, Slingluff CL, Qureshi A, Young TC, Urba WJ (2016) Efficacy and safety of nivolumab (NIVO) alone or combined with ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain in a phase 1 study. [Poster from the Society for Melanoma Research Annual Meeting, 2016]

48.

Kanai O, Fujita K, Okamura M, Nakatani K, Mio T (2016) Severe exacerbation or manifestation of primary disease related to nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastases. Ann Oncol 27(7):1354–1356. https://doi.org/10.1093/annonc/mdw148 CrossRefPubMed

49.

Dudnik E, Yust-Katz S, Nechushtan H, Goldstein DA, Zer A, Flex D, Siegal T, Peled N (2016) Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. Lung Cancer 98:114–117. https://doi.org/10.1016/j.lungcan.2016.05.031 CrossRefPubMed

50.

Bidoli P, Chiari R, Catino A, Grossi F, Noberasco C, Gelsomino F, Gilli M, Proto C, Soto Parra HJ, Migliorino MR, Bonomi L, Tassinari D, Frassoldati A, Albanese V, Fadda GM, Cognetti F, De Galitiis F, Finocchiaro G, Delmonte A (2016) Efficacy and safety data from patients with advanced squamous nsclc and brain metastases participating in the nivolumab expanded access programme (EAP) in Italy. [Abstract from the European Society of Medical Oncology (ESMO) Congress, 2016]

51.

Goldman JW, Crino L, Vokes EE, Holgado E, Reckamp K, Pluzanski A, Spigel D, Kohlhaeufl M, Garassino M, Chow LQ, Gettinger S, Gerber DE, Havel L, Ramalingam SS, Dy GK, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Lopes G (2016) P2.36: Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets): track: immunotherapy. J Thorac Oncol 11(10S):S238-S239. https://doi.org/10.1016/j.jtho.2016.08.107 [Abstract from the European Society of Medical Oncology (ESMO) Congress, 2016].PubMed

52.

Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372(21):2006–2017. https://doi.org/10.1056/NEJMoa1414428 CrossRefPubMedPubMedCentral

53.

Tawbi H, Forsyth PAJ, Algazi AP, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Gonzalez R, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini AA, Jiang J, Avila A, Demelo S, Margolin KA (2017) Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204. [Abstract from the American Society of Clinical Oncology (ASCO) Annual Meeting, 2017]

54.

Liniker E, Menzies AM, Kong BY, Cooper A, Ramanujam S, Lo S, Kefford RF, Fogarty GB, Guminski A, Wang TW, Carlino MS, Hong A, Long GV (2016) Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. Oncoimmunology 5(9):e1214788. https://doi.org/10.1080/2162402X.2016.1214788 CrossRefPubMedPubMedCentral

55.

Gerber NK, Young RJ, Barker CA, Wolchok JD, Chan TA, Yamada Y, Friguglietti L, Beal K (2015) Ipilimumab and whole brain radiation therapy for melanoma brain metastases. J Neurooncol 121(1):159–165. https://doi.org/10.1007/s11060-014-1617-9 CrossRefPubMed

56.

Fang P, Jiang W, Allen P, Glitza I, Guha N, Hwu P, Ghia A, Phan J, Mahajan A, Tawbi H, Li J (2017) Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma. J Neurooncol 133(3):595–602. https://doi.org/10.1007/s11060-017-2470-4 CrossRefPubMed

57.

Silva IP, Johnpulle RAN, Banks PD, Grass GD, Smith JL, Everett AS, Goldinger SM, Roberts-Thomson R, Millward M, Glitza IC, Haydu LE, Atkinson V, Wang T, Eroglu Z, Conry RM, Shackleton MJ, Hong A, Long GV, Johnson DB, Menzies AM (2017) Incidence, features and management of radionecrosis (RN) in melanoma patients (pts) treated with cerebral radiotherapy (RT) and anti-PD-1 antibodies (PD1). [Abstract from the American Society of Clinical Oncology (ASCO) Annual Meeting, 2017]

58.

Mathew M, Tam M, Ott PA, Pavlick AC, Rush SC, Donahue BR, Golfinos JG, Parker EC, Huang PP, Narayana A (2013) Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res 23(3):191–195. https://doi.org/10.1097/CMR.0b013e32835f3d90 CrossRefPubMed

59.

Patel KR, Lawson DH, Kudchadkar RR, Carthon BC, Oliver DE, Okwan-Duodu D, Ahmed R, Khan MK (2015) Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. Neuro Oncol 17(10):1312–1321. https://doi.org/10.1093/neuonc/nov093 CrossRefPubMedPubMedCentral

Titel: Cancer immunotherapy in patients with brain metastases
verfasst von: Salvatore Caponnetto
Arianna Draghi
Troels Holz Borch
Marianna Nuti
Enrico Cortesi
Inge Marie Svane
Marco Donia
Publikationsdatum: 08.03.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 5/2018
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-018-2146-8

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Cancer immunotherapy in patients with brain metastases

Abstract

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2018

Identification of tumor-reactive B cells and systemic IgG in breast cancer based on clonal frequency in the sentinel lymph node

The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models

Certain BCG-reactive responses are associated with bladder cancer prognosis

Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation

The Third Institute for Cancer Vaccines and Immunotherapy (ICVI) symposium on immunotherapy: May 12–13, 2017, Royal Society, London, UK

TriCurin, a synergistic formulation of curcumin, resveratrol, and epicatechin gallate, repolarizes tumor-associated macrophages and triggers an immune response to cause suppression of HPV+ tumors

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie